Need an investment idea? Check out Popular Stocks and S2O Stock Screener.

Market Price

Price is unknown


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Suzuken Co., Ltd., together with its subsidiaries, primarily engages in the wholesale of pharmaceuticals in Japan and internationally. The company operates in four segments: Pharmaceutical Distribution Business, Pharmaceutical Manufacturing Business, Pharmacy Business, and Healthcare-Related Services Business. The Pharmaceutical Distribution Business segment procures ethical drugs, diagnostic reagents, medical equipment and supplies, and other health-related items from manufacturers and supplies to medical institutions and pharmacies. The Pharmaceutical Manufacturing Business segment engages in the research and development, manufacturing, and marketing of ethical pharmaceuticals and diagnostic products focusing on the areas of diabetes and kidney diseases. The Pharmacy Business segment provides services through family pharmacists, as well as improves the operations of local pharmacies and provides educational support. The Healthcare-Related Services Business segment provides manufacturer support services, such as contract distribution for manufacturers; distribution of orphan drugs; and nursing care services, as well as develops, manufactures, and sells electrocardiographs, sphygmomanometers, stethoscopes, medical materials, and health promotion equipment. Suzuken Co., Ltd. also publishes medical magazines for medical institutions. The company has collaboration with Bushu Pharmaceuticals Ltd. provide contract specialty drug services. Suzuken Co., Ltd. was founded in 1932 and is headquartered in Nagoya, Japan.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Mar '12 Mar '13 Mar '14 Mar '15 Mar '16 Mar '17 Mar '18 Mar '19 Mar '20 Mar '21 Mar '22
Equity (BVPS) 33.79
36.12
31.71
growth rate 6.9% -12.2%
Earnings BIT 166.93
245.64
13,241.00
28,244.00
18,712.00
19,737.00
27,229.00
32,572.00
9,158.00
13,778.00
growth rate 47.2% 634.2% 113.3% -33.8% 5.5% 38.0% 19.6% -71.9% 50.5%
Avg.PE 0.20
0.20
0.20
0.20
0.20
0.20
0.20
0.20
21.36
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 10,580.0%
ROA 0.85
1.44
2.10
1.79
2.56
1.86
1.65
2.55
2.45
0.71
growth rate 69.4% 45.8% -14.8% 43.0% -27.3% -11.3% 54.6% -3.9% -71.0%
ROE 2.80
4.79
6.75
5.46
7.61
5.40
4.70
7.49
6.94
1.91
growth rate 71.1% 40.9% -19.1% 39.4% -29.0% -13.0% 59.4% -7.3% -72.5%
ROIC 2.62
4.64
6.60
5.32
7.50
5.33
4.64
7.45
6.91
1.89
growth rate 77.1% 42.2% -19.4% 41.0% -28.9% -13.0% 60.6% -7.3% -72.7%
Cur. Ratio 1.11
1.13
1.15
1.16
1.18
1.21
1.22
1.23
1.27
1.28
growth rate 1.8% 1.8% 0.9% 1.7% 2.5% 0.8% 0.8% 3.3% 0.8%
Quick Ratio 0.86
0.92
0.90
0.94
0.97
0.98
1.02
1.04
1.07
1.08
growth rate 7.0% -2.2% 4.4% 3.2% 1.0% 4.1% 2.0% 2.9% 0.9%
Leverage 3.36
3.28
3.16
2.96
2.99
2.80
2.90
2.97
2.70
2.67
growth rate -2.4% -3.7% -6.3% 1.0% -6.4% 3.6% 2.4% -9.1% -1.1%
Balance Sheet Mar '12 Mar '13 Mar '14 Mar '15 Mar '16 Mar '17 Mar '18 Mar '19 Mar '20 Mar '21 Mar '22
Acct.Receivable 445,655.00
431,860.00
508,760.00
589,748.00
521,609.00
515,322.00
522,632.00
508,192.00
511,261.00
537,304.00
growth rate -3.1% 8.5% 15.9% -11.6% -1.2% 1.4% -2.8% 0.6% 5.1%
Acct.Payable 649,686.00
712,478.00
652,655.00
706,294.00
730,656.00
644,161.00
643,769.00
664,280.00
growth rate 9.7% -8.4% 8.2% 3.5% -11.8% -0.1% 3.2%
Cur.Assets 737,379.00
768,163.00
794,281.00
887,437.00
821,753.00
903,019.00
937,208.00
862,208.00
859,733.00
882,936.00
growth rate 4.2% 1.7% 11.7% -7.4% 9.9% 3.8% -8.0% -0.3% 2.7%
Total Assets 972,076.00
1,014,242.00
1,086,685.00
1,178,435.00
1,109,012.00
1,177,688.00
1,189,238.00
1,112,507.00
1,114,421.00
1,141,717.00
growth rate 4.3% 3.5% 8.4% -5.9% 6.2% 1.0% -6.5% 0.2% 2.5%
Cash 125,180.00
165,333.00
101,504.00
108,463.00
108,276.00
194,969.00
212,579.00
167,521.00
151,123.00
141,377.00
growth rate 32.1% -21.7% 6.9% -0.2% 80.1% 9.0% -21.2% -9.8% -6.5%
Inventory 128,887.00
135,194.00
145,944.00
150,572.00
149,041.00
140,910.00
146,155.00
139,726.00
132,618.00
137,987.00
growth rate 4.9% 3.9% 3.2% -1.0% -5.5% 3.7% -4.4% -5.1% 4.1%
Cur.Liabilities 663,878.00
680,305.00
683,535.00
750,669.00
679,825.00
738,177.00
761,806.00
674,124.00
670,065.00
697,879.00
growth rate 2.5% 0.2% 9.8% -9.4% 8.6% 3.2% -11.5% -0.6% 4.2%
Liabilities 682,569.00
704,700.00
718,888.00
784,338.00
712,517.00
771,264.00
787,615.00
699,800.00
696,511.00
723,656.00
growth rate 3.2% 1.0% 9.1% -9.2% 8.2% 2.1% -11.2% -0.5% 3.9%
LT Debt 462.00
370.00
1,124.00
90.00
15.00
6.00
growth rate -19.9% 74.3% -92.0% -83.3% -60.0%
Equity 289,508.00
309,542.00
367,383.00
393,622.00
395,943.00
405,751.00
400,773.00
411,838.00
417,046.00
417,686.00
growth rate 6.9% 8.9% 7.1% 0.6% 2.5% -1.2% 2.8% 1.3% 0.2%
Common Shares 99.00
99.00
99.00
99.00
99.00
98.00
13,546.00
13,546.00
13,546.00
13,546.00
13,546.00
growth rate 0.0% 0.0% 0.0% 0.0% -1.0% 13,722.5% 0.0% 0.0% 0.0% 0.0%
Cash Flow Statement Mar '12 Mar '13 Mar '14 Mar '15 Mar '16 Mar '17 Mar '18 Mar '19 Mar '20 Mar '21 Mar '22
Capital Expenditures 14,517.00
12,036.00
12,523.00
12,303.00
10,288.00
5,502.00
5,803.00
8,270.00
5,574.00
11,155.00
growth rate -17.1% 2.0% -1.8% -16.4% -46.5% 5.5% 42.5% -32.6% 100.1%
Cash Dividends 5,049.00
4,506.00
5,049.00
5,110.00
6,838.00
5,166.00
6,059.00
6,754.00
6,777.00
6,377.00
growth rate -10.8% 5.9% 1.2% 33.8% -24.5% 17.3% 11.5% 0.3% -5.9%
Cash From OA 65,541.00
54,006.00
47,209.00
20,457.00
27,013.00
98,066.00
41,751.00
-25,817.00
15,602.00
9,520.00
growth rate -17.6% -6.5% -56.7% 32.1% 263.0% -57.4% -100.0% 100.0% -39.0%
FCF per Share -2.82
growth rate
Sale Purchase of Stock 1,997.00
1,997.00
1,997.00
4.00
growth rate 0.0% 0.0% -99.8%
FCF 51,025.00
41,970.00
-52,554.00
30,742.00
4,041.00
14,157.00
90,120.00
32,932.00
-37,515.00
7,738.00
-1,635.00
growth rate -17.8% -100.0% 100.0% -86.9% 250.3% 536.6% -63.5% -100.0% 100.0% -100.0%
Income Statement Mar '12 Mar '13 Mar '14 Mar '15 Mar '16 Mar '17 Mar '18 Mar '19 Mar '20 Mar '21 Mar '22
Sales 1,859,917.00
1,894,594.00
1,969,689.00
2,228,331.00
2,126,993.00
2,123,997.00
2,132,362.00
2,213,478.00
2,128,218.00
2,232,774.00
growth rate 1.9% 2.0% 13.1% -4.6% -0.1% 0.4% 3.8% -3.9% 4.9%
Op.Income 894.00
6,192.00
13,241.00
28,244.00
18,712.00
19,737.00
27,229.00
32,572.00
9,158.00
13,778.00
growth rate 592.6% 46.2% 113.3% -33.8% 5.5% 38.0% 19.6% -71.9% 50.5%
IBT 15,868.00
23,350.00
29,510.00
45,019.00
32,300.00
28,765.00
45,477.00
41,808.00
12,556.00
22,483.00
growth rate 47.2% 12.4% 52.6% -28.3% -10.9% 58.1% -8.1% -70.0% 79.1%
Net Income 8,051.00
14,351.00
18,920.00
28,960.00
21,308.00
18,820.00
30,204.00
28,213.00
7,895.00
14,393.00
growth rate 78.3% 14.8% 53.1% -26.4% -11.7% 60.5% -6.6% -72.0% 82.3%
EPS 81.18
144.72
216.30
190.82
292.13
216.92
198.21
322.73
310.26
88.52
growth rate 78.3% 49.5% -11.8% 53.1% -25.8% -8.6% 62.8% -3.9% -71.5%
Gross Profit 169,721.00
174,999.00
179,631.00
202,463.00
193,225.00
187,512.00
189,295.00
194,124.00
157,841.00
160,994.00
growth rate 3.1% 1.3% 12.7% -4.6% -3.0% 1.0% 2.6% -18.7% 2.0%

Quarterly Statements

Item Name Mar '21 Jun '21 Sep '21 Dec '21 Mar '22
Earnings BIT 2,917.00
-3,591.00
7,466.00
4,130.00
5,773.00
growth rate -100.0% 100.0% -44.7% 39.8%
Balance Sheet Mar '21 Jun '21 Sep '21 Dec '21 Mar '22
Acct.Receivable 511,261.00
526,128.00
517,804.00
554,251.00
537,304.00
growth rate 2.9% -1.6% 7.0% -3.1%
Acct.Payable 643,769.00
671,184.00
666,681.00
798,995.00
664,280.00
growth rate 4.3% -0.7% 19.9% -16.9%
Cur.Assets 859,733.00
906,912.00
897,473.00
1,025,502.00
882,936.00
growth rate 5.5% -1.0% 14.3% -13.9%
Total Assets 1,114,421.00
1,168,542.00
1,163,282.00
1,287,322.00
1,141,717.00
growth rate 4.9% -0.5% 10.7% -11.3%
Cash 151,123.00
145,456.00
143,269.00
210,472.00
141,377.00
growth rate -3.8% -1.5% 46.9% -32.8%
Inventory 132,618.00
140,013.00
138,030.00
159,779.00
137,987.00
growth rate 5.6% -1.4% 15.8% -13.6%
Cur.Liabilities 670,065.00
724,305.00
712,306.00
840,671.00
697,879.00
growth rate 8.1% -1.7% 18.0% -17.0%
Liabilities 696,511.00
753,341.00
740,917.00
867,610.00
723,656.00
growth rate 8.2% -1.7% 17.1% -16.6%
LT Debt
growth rate
Equity 417,046.00
414,284.00
421,395.00
418,823.00
417,686.00
growth rate -0.7% 1.7% -0.6% -0.3%
Common Shares 13,546.00
13,546.00
13,546.00
13,546.00
13,546.00
growth rate 0.0% 0.0% 0.0% 0.0%
Cash Flow Statement Mar '21 Jun '21 Sep '21 Dec '21 Mar '22
Capital Expenditures
growth rate
Cash Dividends
growth rate
Cash From OA
growth rate
FCF
growth rate
Income Statement Mar '21 Jun '21 Sep '21 Dec '21 Mar '22
Sales 521,080.00
539,143.00
558,428.00
586,548.00
548,655.00
growth rate 3.5% 3.6% 5.0% -6.5%
Op.Income 2,917.00
-3,591.00
7,466.00
4,130.00
5,773.00
growth rate -100.0% 100.0% -44.7% 39.8%
IBT 3,250.00
-476.00
13,830.00
5,355.00
3,774.00
growth rate -100.0% 100.0% -61.3% -29.5%
Net Income 1,789.00
-432.00
9,610.00
4,066.00
1,149.00
growth rate -100.0% 100.0% -57.7% -71.7%
EPS
growth rate
Gross Profit 39,913.00
32,180.00
44,402.00
40,613.00
43,799.00
growth rate -19.4% 38.0% -8.5% 7.8%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

F (0.00)

YOY Growth Grade:

F (9.24)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 19.85 19.85
EPS / Growth 1.24

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 1.9%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 1.9% 1.9% 1.9%
Future PE 0.01 1.89 1.89
Future EPS 1.49 1.49 1.49
Value Price
MOS %
0.00
0.70
0.70
MOS Price 0.00 0.35 0.35
IRT

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.